LONDON - Oxford GlycoSciences plc offered an instant rebuff to a cash offer of £101.4 million (US$160 million) from Celltech plc, claiming it was a spoiling tactic to undermine the all-paper deal agreed to with Cambridge Antibody Technology Group plc in January. (BioWorld International)